A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Status:
Completed
Trial end date:
2019-06-24
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, phase 1 safety run-in and phase 2 study of BBI608 in
combination with temozolomide in patients with recurrent or progressive glioblastoma who have
not received prior bevacizumab therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc